Dexamethasone controlled-release implant - pSivida

Drug Profile

Dexamethasone controlled-release implant - pSivida

Alternative Names: Dexamethasone sustained-release - pSivida

Latest Information Update: 19 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator pSivida
  • Developer Hospital for Special Surgery; pSivida
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Corticosteroids; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Osteoarthritis

Most Recent Events

  • 14 Dec 2017 Efficacy and adverse events data from a phase I trial in Osteoarthritis released by pSivida
  • 16 Nov 2016 Chemical structure information added
  • 01 Aug 2016 Phase-I trials in Osteoarthritis in USA (Implant) (9215847; 9206473)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top